Roth Capital Predicts Reduced Earnings for Core Scientific

Key Points

• Roth Capital has reduced its Q4 2026 earnings per share estimate for Core Scientific from $0.03 to $0.01, maintaining a "Neutral" rating with a $17.00 price target.
• The consensus estimate for Core Scientific's full-year earnings is now projected at $0.52 per share, with forecasts for FY2027 and FY2028 standing at $0.16 and $0.99 EPS, respectively.
• Core Scientific's stock has experienced significant fluctuations, recording a fifty-two week low of $6.20 and a high of $18.63, with the current trading price at $13.55.

Core Scientific, Inc. (NASDAQ:CORZ - Free Report) - Equities researchers at Roth Capital dropped their Q4 2026 earnings per share estimates for Core Scientific in a research note issued on Thursday, August 21st. Roth Capital analyst D. Aftahi now forecasts that the company will post earnings per share of $0.01 for the quarter, down from their previous estimate of $0.03. Roth Capital currently has a "Neutral" rating and a $17.00 price target on the stock. The consensus estimate for Core Scientific's current full-year earnings is $0.52 per share. Roth Capital also issued estimates for Core Scientific's FY2027 earnings at $0.16 EPS and FY2028 earnings at $0.99 EPS.

Several other brokerages have also weighed in on CORZ. Oppenheimer reiterated a "market perform" rating on shares of Core Scientific in a research report on Monday, July 7th. Needham & Company LLC lowered Core Scientific from a "moderate buy" rating to a "hold" rating and set a $18.00 price target for the company. in a research report on Thursday, July 10th. Citizens Jmp lowered Core Scientific from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 14th. Craig Hallum lowered Core Scientific from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 7th. Finally, BTIG Research lowered Core Scientific from a "strong-buy" rating to a "hold" rating and set a $20.00 target price for the company. in a report on Monday, July 7th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Core Scientific presently has an average rating of "Hold" and a consensus target price of $18.32.

Core Scientific Stock Performance

Shares of Core Scientific stock opened at $13.55 on Monday. The firm has a market capitalization of $4.14 billion, a price-to-earnings ratio of -24.20 and a beta of 6.60. Core Scientific has a fifty-two week low of $6.20 and a fifty-two week high of $18.63. The stock has a 50 day moving average of $13.97 and a 200 day moving average of $11.06.

Core Scientific (NASDAQ:CORZ - Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.03. The business had revenue of $78.63 million during the quarter, compared to analysts' expectations of $82.09 million. The company's revenue for the quarter was down 44.3% compared to the same quarter last year.

Institutional Trading of Core Scientific

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Tactive Advisors LLC acquired a new stake in shares of Core Scientific during the second quarter worth about $253,000. Castleark Management LLC acquired a new stake in shares of Core Scientific during the second quarter worth about $7,648,000. Tower Research Capital LLC TRC increased its position in shares of Core Scientific by 274.9% during the second quarter. Tower Research Capital LLC TRC now owns 32,843 shares of the company's stock worth $561,000 after purchasing an additional 24,083 shares in the last quarter. Situational Awareness LP increased its position in shares of Core Scientific by 76.8% during the second quarter. Situational Awareness LP now owns 7,994,038 shares of the company's stock worth $136,458,000 after purchasing an additional 3,472,460 shares in the last quarter. Finally, Sandler Capital Management acquired a new stake in shares of Core Scientific during the second quarter worth about $2,920,000.

Insider Transactions at Core Scientific

In other Core Scientific news, Director Yadin Rozov purchased 110,000 shares of the firm's stock in a transaction on Wednesday, May 28th. The stock was bought at an average cost of $10.87 per share, with a total value of $1,195,700.00. Following the acquisition, the director directly owned 475,687 shares of the company's stock, valued at approximately $5,170,717.69. This represents a 30.08% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Todd M. Duchene sold 7,759 shares of Core Scientific stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $12.39, for a total value of $96,134.01. Following the sale, the insider directly owned 2,049,689 shares of the company's stock, valued at $25,395,646.71. This trade represents a 0.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 117,759 shares of company stock valued at $1,391,434 over the last ninety days. 1.40% of the stock is owned by company insiders.

About Core Scientific

Core Scientific, Inc provides digital asset mining services in North America. It operates through two segments, Mining and Hosting. The company offers blockchain infrastructure, software solutions, and services; and operates data center mining facilities. It also mines digital assets for its own account; and provides hosting services for other large bitcoin miners, which include deployment, monitoring, trouble shooting, optimization, and maintenance of its customers' digital asset mining equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.